Why analysts are watching it
Analysts are watching Novo Nordisk (NVO) due to its strategic partnerships and recent performance. On May 11, 2026, Travis Hoium of Asymmetric Investing discussed how a partnership with Hims & Hers could create tailwinds for NVO. The Patient Investor, in a May 7, 2026 video, noted that NVO's new CEO is performing well and the stock is starting to turn. In a May 12, 2026 video, Travis Hoium highlighted that Hims & Hers has fulfilled over 125,000 shipments for WGO products within six weeks of introducing direct access to Novo Nordisk GLP1 products. The Patient Investor also stated on May 11, 2026, that Hims' partnership with NVO has removed regulatory risks and the risk of lawsuits, which is a massive improvement. However, these discussions are largely focused on the impact on Hims & Hers rather than solely on NVO.
Contributing creators
Source clips
"in the second quarter you'd start to transition to the Novo Nordisk to that Nova Nordisk partnership that was announced that's going to potentially have tailwinds for both of these numbers."
— BREAKING: Hims & Hers Earnings Breakdown | The Growth Nobody's Talking About
"This is what's happening with NVO. The new CEO is doing really, really well."
— PayPal Stock Analysis: The Comeback Is Near!
"Within 6 weeks of introducing direct access to Novo Norris GLP1 products on our platform, we have fulfilled more than 125,000 shipments for WGO products."
— HUGE Hims & Hers Stock News Today! $HIMS
"This is what's happening with NVO. The [39s] new CEO is doing really, really well. [41s] The stock is starting to turn."
— PayPal Stock Analysis: The Comeback Is Near!
"But, Hims stopped doing it for them to partner up with NVO, which has removed the regulatory risks on the stock, and it has removed the risk of them being sued, and this is a a massive, massive improvement."
— HIMS STOCK IS CRASHING! Here's Why:
"WGOI and Ozempic. WGOI is going to be the biggest thing there."
— HUGE Hims & Hers Stock News Today! $HIMS